The Fig 5B K6-STAT6-Ub (HA) panel is incorrect; instead of the correct K6 panel, an image of the WT results at a shorter exposure time was used inadvertently.Fig 5 has been updated below to show the correct K6 panel.The underlying image data for the blots presented in Fig 5 are provided in the S1 File below.The Fig 7A iSLK-KSHV GAPDH panel is incorrect, and Fig 7 has been updated to present the correct iSLK-KSHV GAPDH panel.The underlying image data for the blots presented in Fig 7 and the underlying individual level data presented in Fig 7E are provided in the S1 and S2 Files below.In addition to the errors above, the BC3 STAT6, BCBL1 STAT3, and BC3 GAPDH panels of Fig 1A have not been prepared in line with best practice guidelines for image preparation.These panels have been replaced in the updated Fig 1 below to represent the obtained results more accurately.The underlying image data for the blots presented in Fig 1 are provided in the S1 File below.The individual level data underlying the results presented in Figs 1D, 1E, 1F and 1G are provided in the S3-S6 Files below respectively.Furthermore, the authors would like to clarify that the similarities between the Fig 1A BCBL1 STAT6 panel and the Fig 4B BCBL1 STAT6 panel, as well as the similarities between the Fig 1A BCBL1 GAPDH panel, Fig 4B BCBL1 GAPDH panel, and the Fig 7B BCBL1 GAPDH panel are due to these panels being used to represent results obtained from the same experiments.The underlying image data underlying the results presented in Figs 1, 4 and 3 are provided in the S1 File below.
Human papillomavirus (HPV) vaccine is approved by the the U. S. Food and Drug Administration in 2006 for female cancer prevention. There are currently three types of prophylactic HPV vaccines, and its application in developed countries can significantly reduce HPV infection rates and cervical lesion rates. In developing countries, HPV vaccination rates are low due to lack of knowledge of cervical cancer and funds. At the same time, concerns about vaccine safety have led to a reduction in vaccination rates in developed countries. Countries are facing the challenge of increasing vaccination rates.
Key words:
Papillomaviridae; Uterine cervical neoplasms; Papillomavirus vaccines; Primary prevention
Hydroxyapatite nanocrystal (HN) deposition underlies the development of vascular calcification, which is an actively regulated process resembling bone formation. This study investigated the role of HNs in inducing osteogenic differentiation of primary human aortic smooth muscle cells (HASMCs).Primary HASMCs were incubated with HNs, cell osteogenic differentiation was evaluated by von kossa staining and calcium content. The expressions of SM-α-actin and bone markers, including runt-related transcription factor 2 (Runx2), osteopontin (OPN), osterix, and collagen 1 (COL1) were also determined. Antioxidants, ERK-specific inhibitor were used to examine whether oxidative stress and the ERK pathway were required for this transition.Stimulation of HASMCs with HNs increased calcium deposition, expression of bone markers and decreased SM-α-actin expression. HNs produced reactive oxygen species (ROS) in HASMCs, as evaluated by fluorescent probe. Antioxidants inhibited HN-induced osteogenic differentiation. Furthermore, the inhibitor of the ERK pathway, PD98059, suppressed the effect of HNs on bone marker expression.These findings suggest that HNs stimulated osteogenic differentiation of vascular smooth muscle cells that build biomineralized deposits partly by activating oxidative stress and the ERK pathway.
Abstract In China, the prevalence of idiopathic membranous nephropathy (IMN) is increasing with a younger age of onset. From January 2012 to October 2018, biopsy‐proven nephrotic IMN patients aged between 15 and 40 in Taian City Central Hospital treated with tacrolimus (TAC) were retrospectively analyzed. Twelve‐month follow‐up data were collected. A total of 86 patients were enrolled in this study. Forty patients in the TAC group received TAC monotherapy with an initial dose of 0.05 to 0.1 mg/kg/day. Forty‐six patients in the TAC + Pred group received TAC combined with oral prednisone (0.5 mg/kg/day initially). Remission rate, relapse rate, and adverse events in the two groups were assessed. Total remission (TR) rates at the end of the 3rd, 6th, and 12th month were 15%, 35%, and 77.5% (TAC group) and 28.3%, 56.5%, and 80.4% (TAC + Pred group), respectively. Compared with the TAC group, the TAC + Pred group had higher complete remission rates at the end of the 6th and 12th month, and TR rate at the 6th month was significantly higher. Twenty‐four‐hour urinary protein excretion, serum albumin and estimated glomerular filtration rate between the two groups were comparable during the follow‐up. Decrease in proteinuria was significantly greater in the TAC + Pred group. No significant difference of relapse rate was found between the two groups. Adverse effects in the two groups were mild and controllable. Both TAC monotherapy and TAC combined with medium‐dose prednisone are effective and safe for young adults with nephrotic IMN, while TAC + Pred regimen brings more benefits.
Abstract Assisted PD is used as an alternative option for the growing group of frail, older ESKD patients unable to perform their own PD. This study was undertaken to investigate the outcomes of assisted PD in older patients by comparing assisted PD patients with self-care PD patients. This study included all patients aged 70 and above who started on PD in our hospital from 2009 to 2018. Patients were followed up until death, PD cessation or to the end of the study (December 31, 2019). Risk factors associated with mortality, peritonitis and technique failure were evaluated using both cause-specific hazards and subdistribution hazards models. 180 patients were enrolled, including 106 (58.9%) males with a median age of 77.5 (77.2–81.2) years. Among the 180 patients, 62 patients (34.4%) were assisted. Patients on assisted PD group were older, more likely to be female, more prevalent in DM and CVD, with a higher Charlson score than patients undergoing self-care PD ( P all < 0.05). In the multivariable analysis, assisted patients had a comparable patient survival and peritonitis-free survival compared to self-care PD patients either in the Cox or in the FG models. According to a Cox model, the use of assisted PD was associated with a lower risk of technique failure (cs-HR 0.20, 95% CI 0.04–0.76), but the association lost its statistical significance in the Fine and Gray model. Our results suggest that assisted PD could be a safe and effective KRT modality for older ESKD patients who need assistance.
Objective
To evaluation the correlation of serum NT-proBNP and its changes on prognosis of maintenance hemodialysis patients.
Methods
We randomly selected 300 cases of maintenance hemodialysis patients from blood purification center in our hospital. Serum NT-proBNP concentrations were determined at the beginning and after 6 months of dialysis respectively, and followed up the subjects for 1 year. complications and mortality were analyzed the as the effects of NT-proBNP levels and its changes.T-test was further used to dertermined differences between two groups which appeared normal distribution, Rank sum test was further used to dertermined differences between two groups which appeared non-normal distribution. Chi-Square was further used to dertermined differences between count data. Logistic regression analysis was used to test the influence factors.
Results
NT-proBNP levels of 300 maintenance dialysis patients were significantly increased.(1) The primary disease, vascular access and the NT-proBNP levels are associated with cardio cerebral vascular complication in these patients (χ2=7.670、5.293,Z=-2.374,-2.787;P 0.05). Sex, age, primary diseases, vascular access, year of dialysis, NT-proBNP at baseline and 6 months after dialysis were not associated with cardio cerebral vascular complication when using cardio cerebral vascular complications as the dependent factor to do the Logistic regression analysis (P>0.05). (2) Primary disease, vascular access and the NT-proBNP levels are associated with survival in these patients (χ2=8.572, 5.911,Z=-4.447,-5.086;P 0.05). (4) Kaplan-Meier survival analysis showed that NT-proBNP more than 5 000ng/L of patients with an shorter survival time than NT-proBNP lower than 5 000ng/L (χ2=9.964,P<0.05).
Conclusion
The level of NT-proBNP in maintenance hemodialysis patients was increased. The increased NT-proBNP was associated with the risk of cardio cerebral vascular complications and death in hemodialysis patients.
Key words:
Maintenance hemodialysis; NT-pro B type natriuretic peptide; Cardio cerebral vascular complication; The risk of death; Prognosis
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
